Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 17, 2025
Curia ประกาศขยายโรงงานในเครือข่ายโรงงานระดับโลกสำหรับการบรรจุและการตกแต่งแบบปลอดเชื้อ
GlobeNewswire
·
March 17, 2025
ออลบานี นิวยอร์ก, March 17, 2025 (GLOBE NEWSWIRE) -- วันนี้ Curia Global, Inc. (Curia) ซึ่งเป็นองค์กรชั้นนำด้านการวิจัย การพัฒนา และการผลิตตามสัญญา ได้ประกาศแผนการขยายโรงงานที่กลาสโกลว์ สหราชอาณาจักร …
Curia 宣佈擴展全球無菌灌裝生產地點的網絡
GlobeNewswire
·
March 17, 2025
奧爾巴尼，紐約州, March 17, 2025 (GLOBE NEWSWIRE) -- 頂尖的合約研究、開發及製造企業 Curia Global, Inc. (Curia) 今天宣佈擴展其英國格拉斯哥工廠的計劃，並就新墨西哥州阿爾伯克基進行中的擴張計劃披露最新進展。 Curia 位於格拉斯哥的無菌灌裝工廠將會增加一條以隔離器為基礎的整合式小藥瓶灌裝線及冷凍乾燥機，適用於包括高效能藥物在內的多種藥物製品，比目前 GMP 批次規模增加一倍以上。 Curia 已憑著其抗體偶聯藥物 (antibody drug …
VitalHub Announces Q4 2024 Conference Call Date
GlobeNewswire
·
March 17, 2025
TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it will release its financial results for its fourth quarter 2024 ended December 31, 2024, after market close on …
Bon Natural Life Limited Announces Pricing of $12 Million Best Efforts Offering
GlobeNewswire
·
March 17, 2025
XI’AN, China, March 17, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced that it has priced …
New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution
GlobeNewswire
·
March 17, 2025
Data presented at European Molecular Imaging Meeting (EMIM 2025) for imaging with 68Ga-RAD202 confirms specific accumulation in the tumor, favorable biodistribution and low uptake in non-target organs, except for the bladder and kidney as expected …
Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
GlobeNewswire
·
March 17, 2025
FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strategic collaboration aimed at identifying and evaluating …
Myhal Family Foundation Makes Transformative Gift to the Future of St. Joe’s
GlobeNewswire
·
March 17, 2025
TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- St. Joseph’s Health Centre Foundation announced today that major Canadian philanthropists and long-time west-end residents Rayla and George Myhal are making a significant investment in St. Joseph’s Health Centre …
Dentsply Sirona Appoints David Ferguson as Global Business Unit Leader
GlobeNewswire
·
March 17, 2025
CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (XRAY) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025. In …
Lirum Therapeutics Announces Debut of LX-101 Results in Thyroid Eye Disease, Selected for Presentation at the 2025 NANOS Annual Meeting
GlobeNewswire
·
March 17, 2025
New York, NY, March 17, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that its first data on LX-101 in Thyroid Eye …
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
GlobeNewswire
·
March 17, 2025
Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months HIGH POINT, N.C., …
China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency
GlobeNewswire
·
March 17, 2025
TAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (Nasdaq: SXTC) (the “Company”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese …
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire
·
March 17, 2025
Interim data and topline data readouts from Phase 2a biomarker study expected in Q2 2025 and Q3 2025, respectively Cash runway expected to fund operations into Q2 2025, including interim data readout from GRI-0621 LA JOLLA, CA, March 17, 2025 (GLOBE …
Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® Pipeline and Platform
GlobeNewswire
·
March 17, 2025
Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® Pipeline and Platform Financing led by General Catalyst with additional investment from new investors, British Patient Capital, Solasta …
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
GlobeNewswire
·
March 17, 2025
The Annual Meeting is the foremost educational and scientific event for gynecologic oncologists Stenoparib has shown clinical benefit in heavily pre-treated patients, including those with platinum-resistant and refractory ovarian cancer Findings may …
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
March 17, 2025
Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025 MBX 1416 Phase 2 trial in patients with post-bariatric hypoglycemia expected to begin in 2H 2025 Investigational New Drug submission …
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
GlobeNewswire
·
March 17, 2025
-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures -- Former Chair of GSK’s vaccine business and Chief …
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo
GlobeNewswire
·
March 17, 2025
RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea and other …
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
GlobeNewswire
·
March 17, 2025
Nes-Ziona, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the China National Intellectual Property Administration ( …
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
GlobeNewswire
·
March 17, 2025
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement …
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
·
March 17, 2025
-Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary outcome measure- -Plan to initiate Phase 3 trial in mid-2026 …